According to WHO data, the leading mortality cause in the world is cardiovascular diseases (CVDs). Most CVD disease can be traced back to hazardous conduct and risky lifestyle which lead to such ”interim” risk factors as hypertension, high blood lipid level and body fat percentage or obesity. These can be measured independently and routinely in basic health care, or even in day-to-day living conditions using consumer devices, however, their effect and impact on the human body, the detection and early diagnostics of irregularities and deformations developing in the cardiovascular system has not found a satisfactory solution yet. The integrated system of the CardiaCom innovation program can offer efficient solutions for a large number of patients in any of the domains of CVD prevention and early diagnostics, remote care and post-illness rehabilitation.
The Feasibility Study has been developed to verify the technological, practical and economic viability of the innovation concept and to present its novelty to the medical industry. It contains an exploratory part and a planning part.
In the exploratory part of the Feasibility Study the following tasks were the most important:
• Exploration of the attitudes to cardiovascular disease based on the relevant and available statistics
• Definition of the demand of the new technology within the target group
• Attainment of the public opinion about the prevalence of relevant diseases
• Detailed comparison of currently available monitoring devices
• Examination of the technology’s market environment
In the strategic planning part of the Feasibility Study the following tasks were the most important:
• Determining the method of entering the market and elaborating the potential expansion model
• Determining of the optimal business model and analysing of the financial indicators of the project
• Determining of the objectives and tools of the marketing strategy
• Determining of the technological improvement; and the milestones of the project
As a result of demographic and social trends, the demand for consumer medical instruments and remote health services as a whole will show a significant growth over the next decade. The strategic objective of Atractor Ltd. is to understand and supply for, the needs of major user groups, to become a leading international medical instrument manufacturing and trans-national network communication system development company.
The international potential and business orders of magnitude inherent in the products justify the detailed elaboration of a business development plan in view of ensuring the successful product launch, its widespread dissemination, distribution and intense growth on the market. In order to achieve these goals the management decided to submit an application for the H2020 Phase 2 invitation to tender.
